Chrysophanol Protects Against Acute Heart Failure by Inhibiting JNK1/2 Pathway in Rats
Authors:
- 24 August 2020
- journal article
- research article
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 26, e926392-1-e926392-11
Abstract
Background: Acute heart failure (AHF) usually requires urgent therapy. Myocardial damage, oxidative stress, and inflammation are major components in the pathology of AHF. This study was designed to investigate the effects of chrysophanol on AHF. Material/Methods: Sprague-Dawley rats were injected with isoprenaline hydrochloride to construct AHF rat models. AHF rats were treated with normal saline (negative control), chrysophanol, the combination of chrysophanol and SP600125, or benazepril (positive control) using sham rats as blank controls. Echocardiography, histological staining, and enzyme activity analysis were performed to assess the heart functions and myocardial damage. Effects on apoptosis, oxidative stress (OS), and inflammation were evaluated by biochemical analysis, TUNEL staining, and ELISA. Results: Chrysophanol improved the parameters of cardiac functions and alleviated the myocardial damage accompa- nied by the reduction of creatine kinase and lactate dehydrogenase activity. Meanwhile, chrysophanol inhibited the myocardial apoptosis along with the upregulation of Bcl-2 and downregulation of Bax and cleaved caspase-3. AHF-induced abnormal changes of OS parameters (MDA, GPx, CAT, SOD) and inflammatory markers (IL-6, 1L-1 beta, INF-alpha, IFN-gamma) were alleviated by chrysophanol. Benazepril treatment showed similar results with chrysophanol, while the addition of SP600125 enhanced the chrysophanol-mediated protection effects in AHF rats. Western blot analysis demonstrated that chrysophanol inhibited the phosphorylation of JNK1/2 and its upstream/downstream factors. Conclusions: Chrysophanol improved cardiac functions and protected against myocardial damage, apoptosis, OS, and inflammation by inhibiting activation of the JNK1/2 pathway in AHF rat models. These finding indicate that chrysophanol may be a promising approach for treatment of AHF.Keywords
This publication has 46 references indexed in Scilit:
- Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialThe Lancet, 2013
- Neurohormonal Activation in Acute Heart Failure: Results from VERITASCardiology, 2011
- Myocardial oxidative stress contributes to transgenic β2‐adrenoceptor activation‐induced cardiomyopathy and heart failureBritish Journal of Pharmacology, 2010
- Anti-Inflammatory Activity of Chrysophanol through the Suppression of NF-kB/Caspase-1 Activation in Vitro and in VivoMolecules, 2010
- The JNK inhibitor SP600125 enhances dihydroartemisinin‐induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cellsFEBS Letters, 2010
- Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapyHeart Failure Reviews, 2007
- Acute Heart Failure SyndromesCirculation, 2005
- The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathwaysBrain Research, 2005
- Expression of immediate early genes, GATA‐4, and Nkx‐2.5 in adrenergic‐induced cardiac hypertrophy and during regression in adult miceBritish Journal of Pharmacology, 1999
- MAP kinase pathwaysProgress in Biophysics and Molecular Biology, 1999